Guardant’s Multi‑Cancer Blood Test Arrives in India Through Dr Dang’s Lab and Zydus Lifesciences

India’s fight against cancer just got a fresh ally. Dr Dang’s Lab, a name most of us trust for pathology work, has inked a deal with Zydus Lifesciences to roll out Shield™, a blood‑based multi‑cancer detection test developed by Guardant Health.

Why does this matter? Simple, really: cancer rates in the country are climbing – the Indian Council of Medical Research’s National Cancer Registry says we could see a 12‑15 % rise in cases over the next few years. Yet too many people are only diagnosed when the disease is already advanced. Early detection, as doctors everywhere agree, can shift the odds dramatically in favour of the patient.

Enter Shield™. It’s not just another tumour marker; it’s a methylation‑based liquid‑biopsy that looks for DNA clues in a regular blood draw. The test can spot ten common cancers – bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian and pancreatic – in anyone 45 years or older who has a typical, average risk profile.

In the United States, the FDA even gave the test a Breakthrough Device Designation, a nod that underscores its promise in picking up cancers early and even hinting at their tissue of origin. While it’s still an export‑only laboratory‑developed test in the U.S., the technology is now being adapted for Indian patients.

“We’re thrilled to partner with Dr Dang’s Lab and Zydus,” said Simranjit Singh, CEO of Guardant Health for the Middle East, Africa and India. “Making Shield™ accessible here could shrink the stark mortality‑to‑incidence gap we see in India today.” He added a hint of optimism, noting that broader screening could mean fewer late‑stage diagnoses.

From the Indian side, Dr Arjun Dang, CEO of Dr Dang’s Lab, is equally enthusiastic. “Our aim has always been to stay ahead of the curve,” he remarked. “Bringing this test to our network, with home‑sample collection and pan‑India reach, means geography won’t limit anyone from getting a cutting‑edge scan.” He also pointed out that early detection aligns with their commitment to community health.

On the oncology front, Dr Nitesh Rohtagi of Fortis Gurugram echoed the sentiment. “A minimally invasive liquid biopsy that can flag multiple cancers early is a game‑changer for real‑world practice,” he said. “It could push us toward treating cancers when they’re most treatable, ultimately improving survival rates on a national scale.”

Zydus Lifesciences, India’s leading oncology player, framed the partnership as part of its broader vision. A spokesperson noted, “We’re focused on science, access and timely intervention. Adding Shield™ to our portfolio complements our existing companion diagnostics and reinforces our pledge to precision‑led healthcare.”

So, what does this mean for the everyday Indian? If you’re 45 or older and consider yourself at average risk, a simple blood draw could screen for ten cancers at once – no invasive biopsies, no organ‑specific tests. The test is designed to be affordable and widely available through Dr Dang’s Lab’s network, including doorstep sample collection in remote areas.

Of course, it’s not a silver bullet. Experts stress that a positive result would still need follow‑up imaging or tissue confirmation. Still, the ability to flag potential malignancies before symptoms appear is a leap forward in a country where many cancers are caught too late.

In short, the Shield™ launch signals a turning point. It blends cutting‑edge genomics with a pragmatic delivery model, aiming to democratise early cancer detection across India’s diverse landscape. As the partnership rolls out, patients, physicians and policymakers alike will be watching closely – hoping that this blood test truly helps turn the tide against cancer.